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Background: Primary neuroendocrine carcinoma of the breast is a heterogeneous group of rare tumors with
positive immunoreactivity to neuroendocrine markers in at least 50% of cells. Diagnosis also requires that other
primary sites be ruled out and that the same tumor show histological evidence of a breast in situ component.
Primary neuroendocrine carcinoma of the breast rarely presents as locally advanced disease and less frequently
with such widespread metastatic disease as described herein. The review accompanying this case report is the first
to provide an overview of all the cases of primary neuroendocrine carcinoma of the breast published in the
literature and encompasses detailed information regarding epidemiology, histogenesis, clinical and histologic
diagnosis criteria, classification, surgical and adjuvant treatment, as well as prognosis. We also provide
recommendations for common clinical and histologic pitfalls associated with this tumor.
Case presentation: We describe a case of a 51-year-old Hispanic woman initially diagnosed with locally-advanced
invasive ductal carcinoma that did not respond to neodjuvant treatment. After undergoing modified radical
mastectomy the final surgical pathology showed evidence of alveolar-type primary neuroendocrine carcinoma of
the breast. The patient was treated with cisplatin/etoposide followed by paclitaxel/carboplatinum. Thirteen months
after surgery the patient is alive, but developed pulmonary, bone, and hepatic metastasis.
Conclusion: The breast in situ component of primary neuroendocrine carcinoma of the breast may prevail on a
core biopsy samples increasing the probability of underdiagnosing this tumor preoperatively. Being aware of the
existence of this disease allows for timely diagnosis and management. Optimal treatment requires simultaneous
consideration of both the neuroendocrine and breast in situ tumor features.
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Primary neuroendocrine carcinoma of the breast (NECB)
was originally described in breast cancers with carcinoid-
like growth patterns [1,2]. Subsequent reports have
been used to define the common features of NECB
by combining histologic findings with ultrastructural,
molecular, and immunohistochemical data [3,4]. Because
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reproduction in any medium, provided the orsubtypes of breast cancer, primary NECB is difficult to
diagnose and therefore remains under-recognized. Herein
we report the case of a patient initially diagnosed with
invasive ductal carcinoma (IDC) that was postoperatively
found to have a primary NECB. Additionally we provide a
comprehensive review of the literature encompassing
detailed information regarding epidemiology, histogenesis,
clinical and histologic diagnosis criteria, classification,
surgical and adjuvant treatment, as well as prognosis.
We also provide recommendations for common clinical
and histologic pitfalls.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Histopathological findings of the primary alveolar-type
neuroendocrine carcinoma of the breast. The tumor showed solid
nests of cancer cells growing in alveolar-like patterns, which were
separated by fibrovascular stroma and collagen and infiltrated the
ducts and ductules (A). The neuroendocrine tumor component
showed diffuse positive immunoreactivity to chromogranin A
(B) and synaptophysin (C) (original magnification: A: 10× and B, C: 40×).
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A 51-year-old Hispanic woman with no previous medical
history presented with a self-detected lump in her right
breast. Physical examination revealed a 2.0 cm firm mass
in the outer quadrants of the right breast, which was
adhered to the chest wall. The left breast and both axillae
were normal. Mammography revealed a distinctive mass
with microscopic calcifications and spiculation signs in
the upper-outer quadrant of the right breast (BI-RADS 3).
A core needle biopsy of the mass reported high-grade
IDC. Staging workup, which included a chest CT and a
liver ultrasound, was negative for metastatic disease.
The patient was staged with a locally advanced IIIB
(T4aN0M0) breast cancer and underwent neoadjuvant
therapy consisting of four cycles of doxorubicin and
cyclophosphamide followed by 33 sessions of radiation
therapy (total dose, 66 Gy to the site of the tumor and
50 Gy to the rest of the breast and axilla). During the
course of treatment the tumor did not show any significant
change in size; accordingly the patient underwent right
modified radical mastectomy.
On gross examination, a 3.2×1.2 cm firm, grey mass
with infiltrating margins was noted. Histopathologically
the tumor was characterized by small, uniform cancer
cells growing in nests and alveolar-like structures
surrounded by delicate fibrovascular stroma and collagen
that invaded ducts and ductules (Figure 1). Cancer cells
were polygonal, round, and oval shape and had finely
granular nuclear chromatin with uniform and vesicular
nuclei and relatively eosinophilic cytoplasm. Due to these
features immunohistochemistry (IHC) with neuroendocrine
markers was performed. Cancer cells stained positive
for both synaptophysin and chromogranin A (individual
reactivity rate 100%) (Figure 1). A high-grade IDC
component was also observed within the same tumor.
Cancer cells were positive for estrogen receptors (ER)
(reactivity rate 90%) and negative for progesterone
receptors (PR) and HER-2 (HercepTest™ score 0). The
Ki-67 proliferation index was >20%. Axillary lymph nodes
did not harbor metastases. Based on these histological
findings the tumor was classified as an alveolar-type
invasive NECB with IDC.
Postoperatively, the patient was treated with three
cycles each of cisplatin/etoposide followed by paclitaxel/
carboplatinum. She was also started on hormone therapy
(tamoxifen then switched to letrozole). Thirteen months
after surgery the patient was alive, but she unfortunately
developed pulmonary, bone, and hepatic metastases.
Discussion
In the last 50 years histological and immunohistochemical
studies have extended our knowledge about neuroendo-
crine tumors. Different diagnostic technologies allow us to
distinguish pathological changes in endocrine cells. It isnow possible to identify neuroendocrine features morpho-
logically and biochemically within different histological
types of invasive breast cancer. NECB was originally
described in 1963 by Feyrter et al. when several cases of
invasive breast cancer appeared to have a carcinoid growth
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series of patients with breast tumors with the same features
[2]. Later on in 1982 a modified silver stain (grimelius) and
electron microscopy were both routinely used to identify
neurosecretory granules and if present within a tumor the
patient was diagnosed with ‘argyrophilic breast carcinoma’,
a term coined by Azzopardi et al. [5]. Towards the
end of the 1980s chromogranin and synaptophysin were
found to be neuroendocrine differentiation markers and
tumors that were once denominated ‘argylophilic breast
carcinoma’ also tested positive for these markers [6]. It
was only until 2002 when Sapino et al. [7] first suggested
a specific definition for NECB, which was subsequently
adopted by the World Health Organization (WHO) in
2003 as a means of endorsing it as a unique type of
breast cancer [8]. In the WHO classification neuroen-
docrine tumors have been defined as those in which one
or more neuroendocrine markers, such as neuro specific
enolase, chromogranin A, and/or synaptophysin, are
expressed in at least 50% of cancer cells [8]. In addition to
this, diagnosing primary NECB also requires fulfilling two
other criteria: (1) other primary sites must be ruled out
and (2) the tumor must show histological evidence of a
breast in situ component [9].
The prevalence of primary NECB was once reported
to be as high as 12% to 19.5%, but this was based on
early diagnostic criteria, various sources of tissue, and
IHC neuroendocrine markers [10-13]. According to WHO
diagnostic criteria the incidence is reported to actually
range from 0.3% to 0.5% [14,15]. The peer-reviewed litera-
ture reveals that >80 patients have been reported (Table 1).
A significant proportion (59.8%) of these cases was
published after the WHO definition was established in
2003 allowing for consistency with respect to diagnostic
criteria. The majority of cases have been described in
women and so far only two cases in men have been
reported [16,17]. The reported age of incidence ranges
from 20 to 83 years with a higher incidence (60.2%)
occurring in patients aged ≥50 years.
Patients with primary NECB do not have any distinctive
clinical presentation (Table 2). Indeed on clinical examin-
ation the findings are similar to those of any other type of
invasive breast cancer. Nodule(s) size ranges from Tis to
18.0 cm and are not generally associated with axillary
lymphadenopathy. The majority of tumors are <2.0 cm and
patients are staged with early breast cancer. The radio-
logical features may include a highly-dense mass with a
spiculated or microlobulated margin on mamography and/
or a homogenously hypoechoic massive lesion with normal
sound transmission on ultrasonography [14]. It is also pos-
sible for it to be mistaken for benign disease such as fibro-
adenomas or cysts because the tumor may have clear-cut,
circumscribed borders [14]. Distinguishing primary from
metastatic NECB is not achieved with breast imaging [49].Before any further action is taken the NECB must be
classified as ‘primary’ or ‘metastatic’. Physicians should
primarily focus on ruling out breast metastasis from
small cell carcinoma of the lung, the gastrointestinal tract,
pancreas, and the cervix. Metastatic neuroendocrine
carcinoma from other organs cannot be distinguished
from primary NECB because histologically they are similar
[50]. In this case workup with imaging is fundamental.
Differential diagnoses should also include Merkel cell
carcinoma, lymphoma, carcinoid tumor, and melanoma
[41]. Combining clinical data, radiologic findings, and
immunohistochemical stains specific to each tumor provides
sufficient evidence to rule out metastatic sources of NECB
and other primary tumors [11].
Tumors with neuroendocrine immunoreactivity below
the 50% threshold should be considered to have focal
neuroendocrine differentiation. Generally these are
IDC-not-otherwise specified (IDC-NOS) although lobu-
lar or medullary carcinomas can also present this
feature. Breast cancers with focal neuroendocrine differ-
entiation typically have 12% to 18% of IHC-positive neu-
roendocrine cells [12,13,51]. These tumors tend to
resemble common histologic types of breast cancer ra-
ther than NECB in terms of age of presentation, size,
histologic grade, and lymph nodal status [10].
The histogenesis of NECB has not been fully clarified.
An initial theory suggested that NECB cancer cells derived
from argyrophilic cells of neural crest origin that migrated
to the mammary ducts [2]. Another theory supports in situ
development from neuroendocrine cells naturally found in
the breast, but these cells have not been consistently found
by other authors [4,52]. A novel hypothesis suggests that
NECB results from an early divergent differentiation
event in breast carcinogenesis in which neoplastic stem
cells differentiate into both epithelial and endocrine
lines [10,53]. Molecular analysis studies support this theory
because studies have shown that the neuroendocrine
component is clonally related to the intraductal component
[54] and that the whole tumor itself is of the luminal
subtype [55].
Histologically describing the breast in situ component
is important because this determines which adjuvant
treatment regimens are chosen. Simultaneous presence
of an intra-ductal component and the absence of other
primary sites establish the breast as the primary organ of
origin [11,54]. Unlike the histogenesis of other common
types of neuroendocrine carcinoma where there is evidence
of benign neuroendocrine tumors these precursor lesions
are extremely rare in the breast. Of the case reports
published so far, only one has described a tumor with
co-existing NECB and neuroendocrine cell hyperplasia [47].
Kawasaki et al. has also described that neuroendocrine
ductal carcinoma in situ (DCIS) could be considered a
pre-invasive stage of NECB [56]. Neuroendocrine






Author (year) [Ref] Age
(years)/Sex
Site Size (cm)b TNM IS GML NSE CgA/B Syn NSG ER PR HER2/Neu Neoadjuvant Surgical Adjuvant Follow-up
(months)
Outcome
Wade (1983) [18] 52/F R 10.0 T4N1M0 - - + NS NS NS NS Mast/ALND Ch 9 DOD
Jundt (1984) [16] 52/M R NS TxN1M0 NS - + + NS NS NS NS NS Ch/RT 14 DOD
Papotti (1992) [19] 64/F R 2.0 T1N0M0 + - - - - - NS NS NS Mast/ALND NS 44 NED
41/F L 3.5 T2NxM0 + - + - - + - NS NS NS Mast/ALND RT 15 DOD
41/F L 3.0 T2NxM0 + + + + + + - NS NS NS Mast/ALND Ch 14 LR/DOD
69/F L 5.0 T3NxM0 + + + - + + NS NS NS Mast/ALND HT 9 DOD
Papotti (1993) [17] 83/M R 1.5 T1N0M0 + + + + - NS NS NS Mast NS 84 DOD
Francois (1995) [20] 68/F R 4.5 T2N0M0 NS + - - NS - Mast/ALND RT 21 D-NOS
Chua (1997) [21] 45/F L NS T2N0Mx NS NS NS NS NS NS NS NS NS NS BCS NS NS NS
Fukunaga (1998) [22] 56/F R 10.0 T3NxM0 + + + - - NS - Mast/ALND - 48 NED
Samli (2000) [23] 60/F L 8.0 T4N1M0 NS + + NS NS NS Ch Mast/ALND Ch/RT 6 LR
Shin (2000) [24] 43/F R 1.3 T1NxM0 NS + NS NS - - BCS RT 30 NED
44/F L 2.0 T1NxM0 NS + NS NS - - BCS/ALND Ch/RT 27 NED
46/F R 3.4 T2NxM0 NS + NS NS - - Mast/ALND Ch 11 AWM
50/F R 2.2 T2NxM0 + + NS NS - - BCS/ALND Ch/HT 35 NED
51/F R 1.5 T1NxM0 NS + NS NS - - BCS/ALND RT 25 NED
57/F L 2.5 T2NxM0 NS + NS NS - - Mast/ALND Ch 10 NED
62/F L 5.0 T3NxM0 + + NS NS - Ch Mast/ALND Ch/HT 32 AWM
64/F L 1.8 T1NxM0 NS + NS NS - - BCS/ALND Ch 10 NED
70/F L 4.0 T2NxM0 + + NS NS - - BCS/ALND Ch/RT 3 NED
Yamasaki (2000) [25] 41/F R 4.5 T2N0M0 + + - NS NS - BCS/Mast/ALND Ch 16 NED
Salmo (2001) [26] 46/F R 4.0 T2N0M0 + + NS NS NS NS - + NS - BCS Ch/RT 9 NED
Zekioglu (2003) [27] 79/F R 1.5 T1N0M0 + + + - + + NS NS Mast/ALND NS 24 NED
76/F L 2.2 T2N0M0 + + + + + + NS NS BCS NS 18 NED
65/F R 3.5 T2N0M0 + + - + + + NS NS Mast/ALND NS 16 NED
68/F R 7.0 T3N1M0 + + + + - - NS NS Mast/ALND NS 22 NED
69/F R 1.0 T1N0M0 + + + + + + NS NS Mast/ALND NS 12 NED
72/F R 1.5 T1N0M0 + + - + + + NS NS BCS NS 13 NED
60/F R 1.0 T1N0M0 + + + + + + NS NS BCS NS 10 NED




















Table 1 Summary of primary neuroendocrine carcinoma of the breast cases published in the indexed literature (n=83)a (Continued)
60/F L 2.5 T2N0M0 + + - + + + NS NS Mast/ALND NS 54 NED
43/F L 5.0 T2N0M0 + + - + + + NS NS BCS NS NS NED
72/F L 2.7 T2N0M0 + + - + + + NS NS BCS NS NS NED
72/F L 2.7 T2N0M0 + + - + + + NS NS Mast/ALND NS NS NED
Bergman (2004) [28] 61/F L 2.5 T2NxM0 + + - - - - - - Mast/ALND NS NS NS
Bigotti (2004) [29] 56/F L 18.0 T3N1M0 + + - + - - - Ch Mast Ch 14 D-N0S
Jochems (2004) [30] 71/F NS 3.0 T2NxM0 NS + + + + + - - Mast/ALND HT 12 NED
Sridhar (2004) [31] 58/F R 2.0 T1NxM0 NS - - - NS - BCS/ALND Ch/RT 18 NED
Yamamoto (2004) [32] 53/F NS 6.5 T3N2M0 NS + NS NS NS NS NS NS 34 NED
75/F NS 2.0 T2N1M0 NS + NS NS NS NS NS NS 43 NED
Berruti (2004) [33] 59/F NS NS T2N0M0 + + + + + - NS - Mast HT NS AWM
Adegbola (2005) [34] 46/F R 1.0 T1N0M0 NS + + - - - - BCS Ch/RT 48 NED
60/F R 1.7 T1NxM0 + + + - - - - BCS Ch/RT 20 D-NOS
61/F L 1.7 T1NxM0 NS + - - - - BCS Ch/RT 6 AWM
Valdes (2006) [35] 41/F R/MF 1.5 T1NxM0 + + - - NS - Mast/SLNB/Re Ch NS NS
Fujimoto (2007) [36] 40/F L/MF 2.0 T1NxM0 + + + + + + - Mast/SLNB HT 36 NED
Kim (2008) [37] 27/F L 3.2 T2NxM0 NS + + + NS NS NS - BCS/ALND Ch/RT 18 NED
Kinoshita (2008) [9] 31/F L 6.0 T3NxM0 + + + - - - Ch Mast/ALND Ch 9 D-NOS
Stita (2009) [38] 64/F L 3.0 T2NxM0 + + + + + NS - Mast/ALND Ch 8 NED
Yamaguchi (2009) [39] 51/F R 3.0 T2NxM0 NS + + - - - - Mast/ALND Ch 12 AWM
Christie (2010) [40] 61/F L 3.0 T2NxM0 + + + - - - - BCS/ALND Ch 3 D-NOS
Latif (2010) [41] 53 /F R 6.0 T3N0M0 NS + + - - - Ch BCS/SLNB RT NS NS
Honami (2011) [42] 54/F B L: 1.0 T1N0M0 L: + + + + + - - BCS RT 18 NED
R: 1.5 R: +
Kawanishi (2011) [43] 67/F R 0.8 T1NxM0 + + + + + - - BCS/ SLNB HT 12 NED
Nozoe (2011) [44] 57/F R 3.0 T2NxM0 NS + + + + - - Mast/ALND Ch NS NS
Zhang (2011) [45] 29/F B L: 8.5 T1N2M0 L: + + + + + + - - BCS Ch NS NS
R: 2.0 R: +
Su (2012) [46] 75/F L 4.0 T2N0M0 NS + + + + - - Mast/ALND HT 20 NED
Miura (2012) [47] 72/F R/MC 1.5 T1N0M0 Both + + + + + - NS Mast/SLNB NS NS NS
Kawasaki (2012) [48] 41/F L 0.0 TisN0M0 + + + + + NS NS BCS NS 101 NED
45/F R 0.0 TisN0M0 + + + + + NS NS BCS NS 80 NED




















Table 1 Summary of primary neuroendocrine carcinoma of the breast cases published in the indexed literature (n=83)a (Continued)
74/F R 0.0 TisN0M0 + + + + + NS NS BCS NS 91 NED
28/F R 0.0 TisN0M0 + + + + + NS NS Mast NS 77 NED
30/F L 0.0 TisN0M0 + + + + + NS NS BCS NS 86 NED
58/F R 0.0 TisN0M0 + + + + + NS NS BCS NS 96 NED
36/F L 0.0 TisN0M0 + + + + + NS NS BCS NS 64 NED
38/F R 0.0 TisN0M0 + + + + + NS NS Mast NS 69 NED
60/F L 0.1 T1N0M0 + + + + + NS NS BCS NS 84 NED
42/F L 0.1 T1N0M0 + + + + + NS NS Mast NS 73 NED
43/F R 0.1 T1N0M0 + + + + + NS NS BCS NS 80 NED
35/F R 0.1 T1N0M0 + + + + + NS NS BCS NS 100 NED
70/F L 0.1 T1N0M0 + + + + + NS NS Mast NS 93 NED
72/F R 0.1 T1N0M0 + + + + + NS NS Mast NS 66 NED
62/F L 0.1 T1N0M0 + + + + + NS NS BCS NS 88 NED
38/F R 0.2 T1N0M0 + + + + + NS NS BCS NS 85 NED
73/F R 0.3 T1N0M0 + + + + + NS NS Mast NS 71 NED
43/F L 0.4 T1N1M0 + + + + + NS NS BCS NS 86 NED
42/F L 0.5 T1N0M0 + + + + + NS NS BCS NS 96 NED
39/F R 0.5 T1N0M0 + + + + + NS NS Mast NS 74 NED
33/F R 0.7 T1N0M0 + + + + + NS NS Mast NS 92 NED
36/F L 1.5 T1N0M0 + + + + + NS NS BCS NS 99 NED
68/F R 2.5 T2N0M0 + + + + + NS NS Mast NS 68 NED
(2012) [Present case] 51/F R 2.0 T4aN0M0 + + + + - - Ch/RT Mast/ALND Ch/HT 13 AWM
aStudies included in this table are those available in PubMed as of May 31, 2012. Papers that were excluded from this summary are those in which information was not provided explicitly in the description of the case
report or because the results were grouped into cohorts [12,49,57].
bObtained either from clinical history or the final pathology report; for multifocal or multicentric disease the largest tumor was registered.
ALND, axillary lymph node dissection; AWM, alive with metastatic disease; B, bilateral; BCS, breast conserving surgery; CgA/B, chromogranin A and/or B; Ch, chemotherapy; D-NOS, dead, but cause not otherwise
specified; DOD, dead of other disease; ER, estrogen receptors; F, female; GML, Grimelius staining; HT, hormone therapy; IHC, immunohistochemistry; IS, breast in situ component; LR, local recurrence; M, male; Mast,
mastectomy; MC, multicentric; MF, multifocal; NED; no evidence of disease; NS, information not specified; NSE, neuron-specific enolase; NSG, neurosecretory granules; PR, progesterone receptors; R, right; Re,




















Table 2 Representative clinical and histopathological




Age of diagnosis (years) >50
Sex Female>Male
Physical examination
Clinical presentation Single palpable, well-circumscribed
nodule (x:̅ 2.5cm) or nipple discharge.
Nodal status Non-palpable axillary lymph nodes
Carcinoid symptoms Absent
Histopathology
Tumor components Co-existing neuroendocrine and
ductal cancer cell populations possibly
from divergent differentiation of cancer
stem cells (lobular or other types of
breast cancer are rare).
Multifocality or multicentricity Rare
Growth pattern Solid carcinoid-like (most common),
large cell-type, and small/oat cell-type
Cell type Homogenous group of plasmacitoid,
signet ring, clear cell, or small/oat cells
Histopathological features Nuclear palisading; pseudorosette
formation; loss of cell cohesion; intra-
and/or extra-cellular mucin content;
and abundant eosinophilic cytoplasm
and nuclei with stippled (‘salt and
pepper’) chromatin.
Diagnostic markers Most sensitive and specific:
chromogranin A or B and
synaptophysin.
Least specific: neurospecific enolase,
CD56, neurofilament triplprotein,
and bombin or leu.
Hormonal receptors Estrogen/progesterone receptor positive
HER2 negative
Molecular subgroup Luminal A (basal-type has been
documented)
Staging, TisN0M0: 9 (10.9)




a Based on case reports that specified size of the lesion; includes present case.
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because it resembles ductal hyperplasia and intraductal
papilloma and sampling is quite difficult [56].
Primary NECB is not associated with any definitive
gross pathological characteristics. The breast in situ
component of primary NECB is usually found as an
intraductal lesion co-existing with the neuroendocrine
carcinoma component [49].The breast in situ component consistently has histo-
pathological features that include large or dilated ducts
with the luminal spaces completely filled; distinctive cells
with ovoid, polygonal, and spindle shapes; and a low- or
moderate- grade of nuclear atypia [49,57]. Additionally
this specific component creates four pitfalls during
diagnosis: (1) the invasive component of primary NECB
can mimic DCIS [57]; (2) non-specific glandular patterns
within the tumor can lead to a diagnosis of IDC-NOS
[51,57]; (3) cases of invasive lobular carcinoma or carcin-
oma with lobular features may not be recognized as having
neuroendocrine differentiation [57]; and (4) the intra-
ductal component of primary NECB may be mistaken for
atypical intraductal hyperplasia or atypical papilloma
[49,57]. In our case we initially overlooked this tumor be-
cause the IDC component prevailed on the core biopsy
sample and final surgical pathology was necessary to ob-
tain a definitive diagnosis. Over two-thirds of the cases in
the literature report initial misdiagnosis later rectified after
surgery [57].
Histologically the neuroendocrine component resembles
lung and gastrointestinal neuroendocrine tumors. It is
characterized by cellular monotony, nuclear palisading,
pseudorosette formation, loss of cell cohesion, and
abundant eosinophilic cytoplasm and nuclei with stippled
(‘salt and pepper’) chromatin [49,57-59]. Nevertheless these
features per se are not sensitive enough to rule in a
diagnosis because they are inconsistently present [57].
Pathologists mainly rely on using a panel of the most
sensitive and specific IHC neuroendocrine markers
(chromogranin A or B and synaptophysin) [51]. Other
less specific markers, such as neurospecific enolase
[12], CD56 [15], neurofilament triplprotein, and
bombin or leu [12], should be avoided. Negative immu-
noreactivity can be common even in in tumors with a
distinctive morphologic growth pattern strongly suggest-
ive of NECB [51,60]. In such cases, further analyses with
techniques such as in situ hybridization [61] and second
opinion are valid options.
Primary NECB comprises a heterogeneous group of
histologic subtypes that differ from one another depending
on the prevalent growth pattern, cell type, level of invasive-
ness, and prognosis [62]. Several classifications have been
proposed [3,63]. The WHO eventually proposed three
histologic categories (solid carcinoid-like, large cell-type,
and small/oat cell-type) [8], which they derived from the
fact that NECB resembles high-grade small and large cell
neuroendocrine pulmonary carcinoma. On another note
the concomitant presence of neuroendocrine features and
mucin differentiation within the same tumor and even in
the same cell (amphicrine cell) is almost exclusive to NECB
[15,51]. This characteristic led several authors to establish
mucin-producing subtypes [17,51,64]. Although the WHO
does recognize the fact that mucinous differentiation occurs
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to their classification. Recently, primary NECB has been
classified in terms of molecular taxonomy. Gene expression
profiling analysis has shown that this group of tumor is of
the luminal type [55]. Basal-type characteristics have only
been reported in one patient [65].
Patient outcome is not affected by the size of the
neuroendocrine component [10]; instead three histological
parameters (histological grade, mucin production, and
apocrine differentiation) have more significant impact.
The most important histological factor is the histological
grade [66], which is to some extent related to the histologic
subtype. For example, solid neuroendocrine carcinoma
and atypical carcinoids, described as well-differentiated
tumors, have a better prognosis [38] than small cell and
large cell NECB, which are poorly differentiated and have
an unfavorable prognosis [67]. Our case highlights the
impact histological grade has on a patient’s outcome as we
believe this may explain why the patient progressed to
metastasis despite receiving optimal treatment. Mucin
production is highly relevant because solid papillary
carcinomas and mucinous carcinomas produce significantly
longer survival times than other subtypes of NECB with no
mucin content [67,68]. Similarly the presence of apocrine
differentiation has correlated with a better prognosis [69].
Specific recommendations regarding surgical manage-
ment do not exist. Patients should be treated similarly
to IDC whose choice of surgical procedure depends
on the tumor’s location and clinical stage [12,49,70].
Differentiating ‘primary’ from ‘metastatic’ NECB is crucial
because the latter does not justify submitting a patient to
mastectomy and axillary node dissection [49]. Of the
patients reported in the literature 48.3% have undergone
mastectomy and 40% axillary lymph node dissection.
Confirming negative surgical margins can be difficult,
especially from intraoperative frozen sections, because
NECB may have pagetoid involvement or a background of
neuroendocrine cell hyperplasia can produce artifacts
[47,56]. To date there is limited information in the literature
regarding safety of oncoplastic breast conservation and
immediate breast reconstruction. Thus far only one
study has reported the case of a patient that underwent
mastectomy followed by deep inferior epigastric perforator
flap reconstruction, however the authors failed to describe
margin status and disease-free survival [35]. Given the
difficulty in assessing tumor margin status for this type
of tumor, oncoplastic breast conservation and immediate
breast reconstruction may not be beneficial to some
patients with primary NECB.
The real challenge with primary NECB lies in choosing
the ideal type of cytotoxic therapy. Currently there is no
information that indicates what the most efficacious
regimen is, but the general consensus is to treat it with
chemotherapy regimens for common histologic types ofbreast cancer [11,15,62,64] and pulmonary small cell car-
cinoma neuroendocrine carcinoma [11,41,71]. Of the
cases that give detailed information on treatment
(n=39), 28 received neo- and/or adjuvant chemotherapy.
Some examples of the chemotherapy regimens reported
in the literature include fluorouracil/epirubicin/cyclo-
phosphamide followed by docetaxel; etoposimide and
carboplatin or cisplatin; cisplatin/irinotecan; adriamycin
and cytoxan or cisplatin; paclitaxel alone; and cyclophos-
phamide/methotrexate/fluorouracil. Our patient was
treated with cisplatin/etoposimide followed by paclitaxel/
carboplatinum; the former combination is the most widely
used in primary NECB. Radiation therapy appears to be used
to a lesser extent than chemotherapy; only 18 patients have
received it alone or in combination with chemotherapy.
Because breast biomarkers have only recently become
a standard in pathology reports many of the earlier case
reports lack this information. As seen in Table 1 primary
NECB tends to heterogeneously express ER, PR, and
HER-2; this may explain why the overall outcome of
these patients varies so much between different cohorts.
Of the case reports with complete hormone receptor
information available (n=18) 9 were triple negative,
7 were ER/PR positive and HER-2 negative, and the
remaining 2 had other combinations. In this current
case report the patient’s tumor was ER positive and PR and
HER-2 negative and hormone therapy was accordingly
prescribed. The current recommendation is for patients
with primary NECB to receive hormone therapy based on
their hormonal receptor status [49].
At the time of publication of each case report (n=83)
58 patients (69.9%) had no evidence of disease, 8 (9.6%)
were alive with local recurrence or metastasis, 5 (6.0%)
died of other disease, and 12 (14.5%) died of a cause not
specified. Only four cases (4.8%), including ours, of
locally-advanced primary NECB have been described,
but ours was the only to progress to metastatic disease.
In general primary NECB, particularly the small cell
carcinoma subtype, is as aggressive as pulmonary neuro-
endocrine carcinoma [11,24,29]. Both these tumors are
characterized by their resistance to multi-modal cytotoxic
therapies [71]. Our patient is a clear example of this
because although she was treated accordingly limited
benefit was observed as she quickly developed widespread
metastases.
The few studies that give insight into outcome have
mixed results. A study by van Krimpen et al. suggested
that the prognosis does not differ from that of the more
common types of breast cancer [13]. This is in accordance
with Miremadi et al.’s study that reported that cases of
primary NECB have the same mean age, size, histologic
grade, nodal status, and prognosis as their non-primary
NECB counterparts [10]. It has also been suggested that
patients with primary NECB of non-small cell type may
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invasive lobular carcinoma [15,72]. Alternatively other
studies have described a worse outcome overall [62,73].
Several unsolved issues are frequently discussed in the
literature. First of all case series have only analyzed their
patients as a homogenous population without taking into
consideration the different histologic subtypes [11,51]. Sec-
ond, standard prognostic parameters, specifically histo-
logic grade, are not consistently taken into account
when comparing primary NECB cases with non-NECB
[11,51]. In addition to this randomized clinical trials
comparing the different treatment regimens and their
outcomes have not been carried out. All these unsolved
matters are obviously related to the rarity of this tumor.
Interestingly enough many of the studies included in
this review did not provide essential clinical, histologic,
diagnostic, and therapeutic information in their case
report, which makes comparing them difficult. In this re-
spect if future cases of primary NECB could be prospect-
ively and collectively registered in a single international
database encompassing standard epidemiological informa-
tion and stratifying patients according to histological and
molecular subtype then physicians would have a valuable
tool to truly understand this tumor.
Conclusion
Primary NECB has been sporadically reported in the
literature since 1963, but formal diagnostic criteria have
only been available since 2003. Although primary NECB
may have morphological characteristics that resemble
classic neuroendocrine tumors the histopathological
diagnosis can only be made with neuroendocrine markers.
Given that a breast in situ component may prevail on
a core biopsy samples primary NECB may be easily
overlooked preoperatively. Being aware of the existence of
this disease may allow for timely diagnosis. Misdiagnosing
primary NECB is detrimental because patients may not
receive the optimal adjuvant treatment they need. Treating
a patient with primary NECB requires simultaneous
consideration of both the neuroendocrine and breast in
situ tumor components. At the moment it is difficult to
fully understand this rare tumor because issues such as
histogenesis, optimal adjuvant therapy, and prognosis
are still unknown. The limited number of patients in the
literature have presented in different clinical stages and
received different treatment combinations thus the
data summarized in this review should be interpreted
cautiously.
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